Comparison of the cytotoxic response against ovarian cancer by immune effector cells isolated and expanded from normal donors and ovarian cancer patients

References

• American Cancer Society. Cancer Facts and Figures 2010. Atlanta: American Cancer Society; 2010.
   Google Scholar
• McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, . Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1–6.
   PubMed Web of Science ®Google Scholar
• Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, . Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348:203–13.
   PubMed Web of Science ®Google Scholar
• Nelson BH. The impact of T-cell immunity on ovarian cancer outcomes. Immunol Rev. 2008;222:101–16.
   PubMed Web of Science ®Google Scholar
• Ingersoll SB, Patel S, Caballero L, Ahmad S, Edwards D, Holloway RW, Edwards JR. Synergistic cytotoxicity of interferonalpha-2b and interleukin-2 in combination with PBMC against ovarian cancer: development of an experimental model for cellular therapy. Gynecol Oncol. 2009;112:192–8.
   Google Scholar
• Ingersoll SB, Ahmad S, Stoltzfus GP, Patel S, Radi MJ, Finkler NJ, . Functional characterization of a fluorescent highly tumorigenic ovarian cancer line to test cellular therapy in experimental models. Int J Gynecol Cancer. 2011;21:457–65.
   Google Scholar
• Ayello J, van de Ven C, Cairo E, Hochberg J, Baxi L, Satwani P, Cairo MS. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy. Exp Hematol. 2009;37:1216–29.
   PubMed Web of Science ®Google Scholar
• Korzeniewski C, Callewaert DM. An enzyme-release assay for natural cytotoxicity. J Immunol Meth. 1983;64:313–20.
   PubMed Web of Science ®Google Scholar
• Decker T, Lohmann-Matthes ML. A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J Immunol Meth. 1988;115:61–9.
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, . Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nature Med. 1996;2:1096–103.
   PubMed Web of Science ®Google Scholar
• Liu VC, Wong LY, Jang T, Shah AH, Park I, Yang X, . Tumor evasion of the immune system by converting CD4 + CD25– T cells into CD4 + CD25 + T regulatory cells: role of tumor-derived TGF-beta. J Immunol. 2007;178:2883–92.
   PubMed Web of Science ®Google Scholar
• Curiel TJ. Tregs and re-thinking cancer immunotherapy. J Clin Invest. 2007;117:1167–74.
   PubMed Web of Science ®Google Scholar
• Quesnel B. Tumor dormancy and immunoescape. Acta Pathol. Microbiol. Immunol. Scand. APMIS. 2008;116:685–94.
   Google Scholar
• Saunier EF, Akhurst RJ. TGF-beta inhibition for cancer therapy. Curr Cancer Drug Targets. 2006;6:565–78.
   PubMed Web of Science ®Google Scholar
• Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683–765.
   PubMed Web of Science ®Google Scholar
• Elgert KD, Alleva DG, Mullins DW. Tumor-induced immune dysfunction: the macrophage connection. J Leukoc Biol. 1998; 64:275–90.
   PubMed Web of Science ®Google Scholar
• Liu Z, Guo B, Lopez RD. Expression of intercellular adhesion molecule (ICAM)-1 or ICAM-2 is critical in determining sensitivity of pancreatic cancer cells to cytolysis by human gammadelta-T cells: implications in the design of gammadelta-T-cell-based immunotherapies for pancreatic cancer. J Gastroenterol Hepatol. 2009;24:900–11.
   PubMed Web of Science ®Google Scholar
• Piali L, Hammel P, Uherek C, Bachmann F, Gisler RH, Dunon D, Imhof BA. CD31/PECAM-1 is a ligand for alpha v beta 3 integrin involved in adhesion of leukocytes to endothelium. J Cell Biol. 1995;130:451–60.
   PubMed Web of Science ®Google Scholar
• Staveley-O’Carroll K, Sotomayor E, Montgomery J, Borrello I, Hwang L, Fein S, . Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci USA. 1998;95:1178–83.
   PubMed Web of Science ®Google Scholar
• Rodríguez PC, Ochoa AC. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev. 2008;222:180–91.
   PubMed Web of Science ®Google Scholar
• Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, . A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy. 2011;13:98–107.
   PubMed Web of Science ®Google Scholar
• Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2009;58:49–59.
   PubMed Web of Science ®Google Scholar
• Almand B, Clark JI, Nikitina E, van Beyen J, English NR, Knight SC, . Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol. 2001;166:678–89.
   PubMed Web of Science ®Google Scholar
• Carlsten M, Björkström NK, Norell H, Bryceson Y, van Hall T, Baumann BC, . DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. Cancer Res. 2007;67:1317–25.
   PubMed Web of Science ®Google Scholar
• Satwani P, van de Ven C, Ayello J, Cairo D, Simpson LL, Baxi L, Cairo MS. Interleukin (IL)-15 in combination with IL-2, fms-like tyrosine kinase-3 ligand and anti-CD3 significantly enhances umbilical cord blood natural killer (NK) cell and NK-cell subset expansion and NK function. Cytotherapy. 2011;13:730–8.
   PubMed Web of Science ®Google Scholar
• Raulet DH, Held W. Natural killer cell receptors: the offs and ons of NK cell recognition. Cell. 1995;82:697–700.
   PubMed Web of Science ®Google Scholar
• Kärre K. Express yourself or die: peptides, MHC molecules, and NK cells. Science. 1995;267:978–9.
   PubMed Web of Science ®Google Scholar